Sanofi's Autoimmune Bispecific Antibody Succeeds in Two Phase II Trials; Gilead's Long-Acting HIV Prevention Drug Nominated for Priority Review
Sanofi
Pharmaceutical Manufacturer
Gilead Sciences
Innovative Drug Developer, Distributor
Conmind
Cardiovascular and Cerebrovascular Interventional Products R&D and Manufacturer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Sanofi Advances Further in the Development of Dual Antibody for Autoimmune Diseases.
On April 7, Sanofi announced that the Phase II studies of lunsekimig, a TSLP/IL-13 dual antibody, conducted in two chronic respiratory diseases, have both met the primary and key secondary endpoints. In both studies, lunsekimig was well-tolerated with an acceptable safety profile.
Gilead Sciences' Long-Acting HIV Prevention Drug Proposed for Priority Review.
On April 7, according to the CDE official website, Gilead's Lenapavir Sodium Tablets and Lenapavir Sodium Injection new indications are proposed to be included in the priority review, applicable for use in combination with safe sexual practices for pre-exposure prophylaxis in adults and adolescents (weighing at least 35kg or more) at higher risk of infection, to reduce the risk of acquiring HIV-1 through sexual activity.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) CONMIND MEDICAL Completes Nearly 200 Million Yuan in Series C Financing
On April 7, Conmind, a brain medicine technology platform, completed a nearly 200 million yuan C-round financing.
/ 02 /
Pharmaceutical News
1) Gilead Sciences' Long-Acting HIV Prevention Drug Proposed for Priority Review
On April 7, according to the CDE official website, Gilead's Lenapavir Sodium Tablets and Lenapavir Sodium Injection new indications are proposed to be included in the priority review, applicable for use in combination with safe sexual practices for pre-exposure prophylaxis in adults and adolescents (weighing at least 35kg or more) at higher risk of infection, to reduce the risk of HIV-1 infection through sexual activity.
2) The world's first BCL6 PROTAC approved for clinical trials
Recently, according to the CDE website, BMS's globally first-in-class BCL6 PROTAC drug, BMS-986458 tablets, has been approved for clinical use in relapsed/refractory non-Hodgkin lymphoma.
3) Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd.'s SYH2069 Injection Receives Clinical Approval
On April 7, according to the CDE official website, Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd.'s SYH2069 Injection received clinical approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
/ 03 /
Overseas Pharmaceutical News
1) Sanofi's TSLP/IL-13 Dual Antibody Achieves Success in Two Phase II Studies
On April 7, Sanofi announced that the Phase II studies of TSLP/IL-13 dual antibody lunsekimig in two chronic respiratory diseases have both met the primary and key secondary endpoints. In both studies, lunsekimig was well tolerated with an acceptable safety profile.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
